Moleculin Reports Positive MIRACLE Trial Results
HOUSTON, July 6, 2026 Moleculin Biotech announced that Chairman and Chief Executive Officer Walter Klemp discussed encouraging preliminary results...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
HOUSTON, July 6, 2026 Moleculin Biotech announced that Chairman and Chief Executive Officer Walter Klemp discussed encouraging preliminary results...
MENLO PARK, Calif., June 30, 2026 Orca Bio announced that the U.S. Food and Drug Administration (FDA) has approved...
SHANGHAI, June 23, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND)...
SOUTH SAN FRANCISCO, Calif., June 15, 2026 IDEAYA Biosciences has announced the initiation of a Phase 1/2 clinical combination...
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
COPENHAGEN, Denmark, June 11, 2026 Evaxion A/S announced new preclinical data for EVX-04, its off-the-shelf therapeutic cancer vaccine being...
CAMBRIDGE, UK, June 8, 2026 Amphista Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the...
WALTHAM, Massachusetts, USA, June 2, 202 Stelexis BioSciences has announced encouraging Phase 1 clinical trial results for eganelisib, its...
WATERTOWN, Massachusetts, USA & DRESDEN, Germany, June 2, 2026 AvenCell Therapeutics has announced that it will present results from...
NEW YORK, May 29, 2026 Actinium Pharmaceuticals, Inc. has announced the receipt of two patent allowances from the Canadian...
